Skip to main content
Download PDF

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

BMC Cancer volume 18, Article number: 1288 (2018) Cite this article

The Original Article was published on 03 December 2018

Correction to: BMC Cancer (2018) 18:1198

DOI: 10.1186/s12885-018-5110-2

Following publication of the original article [1], the authors notified us of a typographical error in Table 1.

Table 1 Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (n = 125) in our cohort
Full size table

The corrected Table 1 is presented below.

Reference

  1. Tan, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018, 2018;18:1198. https://doi.org/10.1186/s12885-018-5110-2.

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

    Wan-Ling Tan, Quan Sing Ng, Eng Huat Tan, Chee Keong Toh, Mei-Kim Ang, Ravindran Kanesvaran, Amit Jain, Daniel S. W. Tan & Darren Wan-Teck Lim

  2. Clinical Trials & Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore

    Cindy Lim

  3. Genome Institute of Singapore, A*STAR, Singapore, Singapore

    Daniel S. W. Tan

  4. Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore

    Darren Wan-Teck Lim

Authors
  1. Wan-Ling Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quan Sing Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cindy Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eng Huat Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chee Keong Toh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mei-Kim Ang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ravindran Kanesvaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amit Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel S. W. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Darren Wan-Teck Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darren Wan-Teck Lim.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, WL., Ng, Q.S., Lim, C. et al. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 18, 1288 (2018). https://doi.org/10.1186/s12885-018-5215-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-018-5215-7

BMC Cancer

ISSN: 1471-2407

Contact us